Who We Are

We are a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors (GPCRs) to address unmet medical needs.

“We are driven to deliver best-in-class pharmaceuticals that address unmet medical needs and improve the health of patients. BELVIQ is our first product from our GPCR-focused drug discovery and development approach, and we are focused on exploring its potential for other indications, formulations and combinations, as well as advancing our internally discovered pipeline of novel drug candidates.”
-Jack Lief, President and Chief Executive Officer